Trial Profile

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; HMPL-760 (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors HUTCHMED

23 Mar 2026 According to a HUTCHMED media release, the company has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma.. The first patient received the first dose on March 20, 2026.
23 Mar 2026 Status changed from not yet recruiting to recruiting, according to a HUTCHMED media release.
18 Feb 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com